The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Muphoran     1-(2-chloroethyl)-3-(1...

Synonyms: Mustoforan, Fotemustina, Fotemustine, Fotemustinum, Mustophorane, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Fotemustine


High impact information on Fotemustine


Chemical compound and disease context of Fotemustine


Biological context of Fotemustine


Anatomical context of Fotemustine


Associations of Fotemustine with other chemical compounds


Gene context of Fotemustine


Analytical, diagnostic and therapeutic context of Fotemustine


  1. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. Avril, M.F., Aamdal, S., Grob, J.J., Hauschild, A., Mohr, P., Bonerandi, J.J., Weichenthal, M., Neuber, K., Bieber, T., Gilde, K., Guillem Porta, V., Fra, J., Bonneterre, J., Saïag, P., Kamanabrou, D., Pehamberger, H., Sufliarsky, J., Gonzalez Larriba, J.L., Scherrer, A., Menu, Y. J. Clin. Oncol. (2004) [Pubmed]
  2. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. Leyvraz, S., Spataro, V., Bauer, J., Pampallona, S., Salmon, R., Dorval, T., Meuli, R., Gillet, M., Lejeune, F., Zografos, L. J. Clin. Oncol. (1997) [Pubmed]
  3. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule. Khayat, D., Lokiec, F., Bizzari, J.P., Weil, M., Meeus, L., Sellami, M., Rouesse, J., Banzet, P., Jacquillat, C. Cancer Res. (1987) [Pubmed]
  4. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Vassal, G., Boland, I., Terrier-Lacombe, M.J., Watson, A.J., Margison, G.P., Vénuat, A.M., Morizet, J., Parker, F., Lacroix, C., Lellouch-Tubiana, A., Pierre-Kahn, A., Poullain, M.G., Gouyette, A. Clin. Cancer Res. (1998) [Pubmed]
  5. Human Monocytes, but not Dendritic Cells Derived from Them, Are Defective in Base Excision Repair and Hypersensitive to Methylating Agents. Briegert, M., Kaina, B. Cancer Res. (2007) [Pubmed]
  6. Candidate genes for cross-resistance against DNA-damaging drugs. Wittig, R., Nessling, M., Will, R.D., Mollenhauer, J., Salowsky, R., Münstermann, E., Schick, M., Helmbach, H., Gschwendt, B., Korn, B., Kioschis, P., Lichter, P., Schadendorf, D., Poustka, A. Cancer Res. (2002) [Pubmed]
  7. O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Lee, S.M., Thatcher, N., Margison, G.P. Cancer Res. (1991) [Pubmed]
  8. Mechanism of action of fotemustine, a new chloroethylnitrosourea anticancer agent: evidence for the formation of two DNA-reactive intermediates contributing to cytotoxicity. Hayes, M.T., Bartley, J., Parsons, P.G., Eaglesham, G.K., Prakash, A.S. Biochemistry (1997) [Pubmed]
  9. Treatment of metastatic malignant melanoma with dacarbazine plus fotemustine. Seeber, A., Binder, M., Steiner, A., Wolff, K., Pehamberger, H. Eur. J. Cancer (1998) [Pubmed]
  10. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: comparison of oral, intravenous, and hepatic intra-arterial administration. Marzolini, C., Decosterd, L.A., Shen, F., Gander, M., Leyvraz, S., Bauer, J., Buclin, T., Biollaz, J., Lejeune, F. Cancer Chemother. Pharmacol. (1998) [Pubmed]
  11. Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines. Merlin, J.L., Marchal, S., Ramacci, C., Berlion, M., Poullain, M.G. Anticancer Drugs (2002) [Pubmed]
  12. In vitro sensitivity of human melanoma cells to chemotherapeutic agents and interferons. Schadendorf, D., Jurgovsky, K., Worm, M., Czarnetzki, B.M. Melanoma Res. (1994) [Pubmed]
  13. Alterations of DNA repair in melanoma cell lines resistant to cisplatin, fotemustine, or etoposide. Rünger, T.M., Emmert, S., Schadendorf, D., Diem, C., Epe, B., Hellfritsch, D. J. Invest. Dermatol. (2000) [Pubmed]
  14. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Christmann, M., Pick, M., Lage, H., Schadendorf, D., Kaina, B. Int. J. Cancer (2001) [Pubmed]
  15. Clinical and pharmacokinetic phase II study of fotemustine in refractory and relapsing multiple myeloma patients. Dumontet, C., Jaubert, J., Sebban, C., Bouafia, F., Ardiet, C., Tranchand, B., Berger, E., Lucas, C., Guyotat, D., Coiffier, B. Ann. Oncol. (2003) [Pubmed]
  16. Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Gander, M., Leyvraz, S., Decosterd, L., Bonfanti, M., Marzolini, C., Shen, F., Liénard, D., Perey, L., Colella, G., Biollaz, J., Lejeune, F., Yarosh, D., Belanich, M., D'Incalci, M. Ann. Oncol. (1999) [Pubmed]
  17. Molecular mechanisms of toxic effects of fotemustine in rat hepatocytes and subcellular rat liver fractions. Brakenhoff, J.P., Commandeur, J.N., Wormhoudt, L.W., Groot, E.J., Vermeulen, N.P. Carcinogenesis (1996) [Pubmed]
  18. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study. Iliadis, A., Launay-Iliadis, M.C., Lucas, C., Fety, R., Lokiec, F., Tranchand, B., Milano, G. Eur. J. Cancer (1996) [Pubmed]
  19. Fotemustine in patients with advanced gastric cancer, a phase II trial from the EORTC-GITCCG (European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group). Rougier, P., van Pottelsberghe, C., Kok, T., Paillot, B., Wagener, T., De Greve, J., Fabri, M.C., Gerard, B., Van Glabbeke, M., Bleiberg, H. Eur. J. Cancer (1996) [Pubmed]
  20. Mutagenicity to Salmonella, Drosophila and the mouse bone marrow of the human antineoplastic agent fotemustine: prediction of carcinogenic potency. Ashby, J., Vogel, E.W., Tinwell, H., Callander, R.D., Shuker, D.E. Mutat. Res. (1993) [Pubmed]
  21. Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains. Shelton, C.J., Harding, M.M., Prakash, A.S. Biochemistry (1996) [Pubmed]
  22. Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. Kaina, B., Mühlhausen, U., Piee-Staffa, A., Christmann, M., Garcia Boy, R., Rösch, F., Schirrmacher, R. J. Pharmacol. Exp. Ther. (2004) [Pubmed]
  23. Chemical and glutathione conjugation-related degradation of fotemustine: formation and characterization of a glutathione conjugate of diethyl (1-isocyanatoethyl)phosphonate, a reactive metabolite of fotemustine. Brakenhoff, J.P., Commandeur, J.N., de Kanter, F.J., van Baar, B.L., Luijten, W.C., Vermeulen, N.P. Chem. Res. Toxicol. (1994) [Pubmed]
  24. Expression of DNA repair proteins hMSH2, hMSH6, hMLH1, O6-methylguanine-DNA methyltransferase and N-methylpurine-DNA glycosylase in melanoma cells with acquired drug resistance. Lage, H., Christmann, M., Kern, M.A., Dietel, M., Pick, M., Kaina, B., Schadendorf, D. Int. J. Cancer (1999) [Pubmed]
  25. Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Tsaryk, R., Fabian, K., Thacker, J., Kaina, B. Cancer Lett. (2006) [Pubmed]
  26. New aspects in the pathophysiology of cutaneous melanoma: a review of the role of thioproteins and the effect of nitrosoureas. Schallreuter, K.U., Wood, J.M. Melanoma Res. (1991) [Pubmed]
  27. The treatment of metastatic uveal melanoma. Pyrhönen, S. Eur. J. Cancer (1998) [Pubmed]
  28. Phase I pharmacological study of intra-arterially infused fotemustine for colorectal liver metastases. Hartmann, J.T., Schmoll, E., Bokemeyer, C., Fety, R., Lucas, C., Giroux, B., Schmoll, H.J. Eur. J. Cancer (1998) [Pubmed]
WikiGenes - Universities